Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

The majority of breast cancers express the estrogen receptor (ER) and are dependent on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for these tumors. However, a superior outcome is achieved in a subset of ER positive (ER(+))/human epidermal growth factor rec...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cells
Κύριοι συγγραφείς: Lorito, Nicla, Bacci, Marina, Smiriglia, Alfredo, Mannelli, Michele, Parri, Matteo, Comito, Giuseppina, Ippolito, Luigi, Giannoni, Elisa, Bonechi, Martina, Benelli, Matteo, Migliaccio, Ilenia, Malorni, Luca, Chiarugi, Paola, Morandi, Andrea
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: MDPI 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140692/
https://ncbi.nlm.nih.gov/pubmed/32164162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030668
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια